Wall Street Zen Downgrades Evolus to 'Hold'

Analysts cite concerns over the company's future performance.

Mar. 15, 2026 at 5:11am

Got story updates? Submit your updates here. ›

Wall Street Zen has downgraded Evolus (NASDAQ:EOLS) from a 'buy' rating to a 'hold' rating in a recent research report. The analysts cited uncertainty around the company's future performance as the reason for the rating change.

Why it matters

Evolus is a specialty pharmaceutical company focused on medical aesthetics, with its flagship product Jeuveau being a key driver of its business. The downgrade from Wall Street Zen could impact investor sentiment and the stock price, potentially affecting the company's ability to execute on its growth plans.

The details

In the research report, Wall Street Zen analysts lowered their price target for Evolus from $20.00 to $17.00 and cited concerns over the company's future performance. The downgrade comes after several other brokerages, including Mizuho and Stifel Nicolaus, have also recently weighed in on Evolus, with mixed ratings and price targets.

  • Wall Street Zen issued the downgrade on Sunday, March 15, 2026.

The players

Evolus

A specialty pharmaceutical company focused on medical aesthetics, headquartered in Newport Beach, California.

Wall Street Zen

A research firm that provides analysis and ratings on publicly traded companies.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Evolus' upcoming financial results and any further updates from the company and analysts to gauge the long-term outlook for the stock.

The takeaway

The downgrade from Wall Street Zen highlights the uncertainty surrounding Evolus' future prospects, underscoring the need for the company to execute flawlessly on its growth strategy to maintain investor confidence.